Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gateway Genomics LLC maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The current prosecution activity is limited to 1 pending office action. This workload is handled by 1 distinct examiner and 1 distinct art unit, reflecting a streamlined examination process for the company's current filings. This concentration suggests that the company's intellectual property is focused on a specific technical application that falls under the jurisdiction of the specialized group at the USPTO.
The busiest examiner identified in the data is HORLICK, KENNETH R. This examiner is currently managing 1 busiest examiner pending action, which represents the total volume of pending actions for the portfolio. Such a focused distribution means that the company's immediate prosecution success relies on the interactions with this specific examiner in the distinct art unit. For practitioners, this highlights the importance of understanding the examiner's past decisions and preferences, as their review will determine the outcome for the 1 pending office action currently active.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HORLICK, KENNETH R | 1 | 79.0% | +15.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18607329 | METHODS, COMPOSITIONS, AND KITS FOR DETERMINING THE SEX OF A FETUS | HORLICK, KENNETH R | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18607329 | METHODS, COMPOSITIONS, AND KITS FOR DETERMINING THE SEX OF A FETUS | HORLICK, KENNETH R | 1681 | DP | Non-Final OA | — | Pending | Mar 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGateway Genomics LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Kenneth R Horlick has the most, with 1 of Gateway Genomics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.